The insider sales are small in magnitude and by a venture capital investor, not management. This is likely a routine portfolio reduction and does not warrant a bearish read-through. Monitor for any C-suite selling or a material increase in sales volume, which would be a stronger signal. The stock's 86% analyst bullish consensus and recent strong institutional accumulation (7 funds doubling positions) provide a counterweight.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 27 $7.27entry
- T+1 · 3mo ago −3.71%α −3.49% · $7.00
- T+5 · 3mo ago −1.38%α −1.64% · $7.17
- T+20 · 8w ago −14.44%α −13.93% · $6.22
- T+56 · todayOpen
- T+60 · in 3d Pending
Price Chart
How similar events traded
Executive Summary
Two MPM BioVentures funds, each a 10% owner of Entrada Therapeutics, sold a combined ~$400K in open-market sales over three days (Aug 24-26). The total value is 0.13% of the $297M market cap, falling in the modest proportionality band. No C-suite insiders participated, and the sales are likely part of a routine portfolio reduction by a venture capital investor, not a signal of operational deterioration. The cluster is a sell, but the dollar amount is small relative to company size and lacks executive participation, limiting its informational value.
Key Financial Metrics
Key Facts
- Two MPM BioVentures funds (10% owners) sold a combined ~$400K in open-market sales over three days.
- Total sales represent ~0.13% of TRDA's $297M market cap.
- No C-suite executives (CEO, CFO, etc.) participated in the sales.
- Sales occurred at prices between $7.06 and $7.54 per share.
- The selling is by a venture capital investor, not company management.
Financial Impact
Total insider sales of approximately $400,000, representing 0.13% of market capitalization.
Risk Factors
- Venture capital selling could continue if the funds are reducing their position over time.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-TRDA-1787794151315 |
Track record
21 reports on TRDA
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +58.22% at T+20 after the May 4, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $4.55 Now $5.00 +9.89% settles Feb 3
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $4.55 Now $5.00 +9.89% settles Jan 11
- Sep 9, 20269w ago Insider Cluster Bearish 6/10 Entry $6.42 Now $5.00 +22.12% settles Dec 4
- Sep 3, 202610w ago Insider Cluster Neutral 3/10 Entry $7.13 Now $5.00 −29.87% settles Dec 1
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 3/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Viewing Entry $7.27 Now $5.00 −31.22% settles Nov 20
- Aug 10, 202614w ago Insider Cluster Neutral 2/10 Entry $7.04 to $5.06 Now $5.00 −28.98% ▼ −28.13% −27.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers